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Objectives. This study sought to assess the impact of generalist 
versus specialist direction on the pattern of care and outcome in 
patients admitted to the hospital for unstable angina. 
Background. Physicians trained as internists or as cardiolo- 
gists may have different approaches to treating patients with 
unstable angina. 
Methods. We reviewed a prospectively collected cohort of 
patients discharged with a diagnosis-related group (DRG) diag- 
nosis of unstable angina from William Beaumont Hospital, a large 
community-based hospital in southeast Michigan. Of 890 consec- 
utive patients, 225 were treated by internists and 665 by cardiol- 
ogists. We compared these two groups with respect o patterns of 
use of established pharmacotherapies for unstable angina, diag- 
nostic testing and clinical outcome. 
Results. Patients treated by internists less often had a previous 
cardiac history (53% vs. 80%, p < 0.0001). Internists were less 
likely to use aspirin (68% vs. 78%, p = 0.032), heparin (67% vs. 
84%, p -< 0.001) or beta-adrenergic blocking agents (18% vs. 30%, 
p -< 0.004) in their initial management. Exercise tests were 
performed more frequently by internist-treated patients (37% vs. 
22%, p < 0.001), but catheterization (27% vs. 61%, p <- 0.0001) 
and angioplasty (7% vs. 40%, p < 0.0001) were utilized less 
frequently. The incidence of myocardial infarction was similar 
(11% vs. 9%) in the two groups, but the mortality rate tended to be 
higher (4.0% vs. 1.8%, p = 0.06) in the internist group. 
Conclusions. Patients with unstable angina treated by inter- 
nists were less likely to receive effective medical therapy or 
revascularization procedures and experienced a trend to poorer 
outcome. This study does not support a positive gatekeeper role 
for generalists in the treatment of unstable angina. 
(J Am Coll Cardiol 1995;26:577- 82) 
Unstable angina pectoris remains an ill-defined clinical entity, 
constituting that part of the clinical spectrum of coronary 
artery disease between chronic stable angina and acute myo- 
cardial infarction. In 1990, >525,000 patients were admitted to 
hospitals in the United States with the diagnosis of unstable 
angina (1). In most hospitals, this diagnosis is the most 
common diagnosis-related group (DRG) entity among acute 
care cardiology discharge diagnoses. As such, unstable angina 
accounts for a substantial portion of health care expenditures 
in the United States. 
In the late 1970s and 1980s, a series of clinical studies 
established the therapeutic benefits of beta-adrenergic (2,3) 
and calcium channel blocking agents (4), aspirin (5-8), heparin 
(9-11) and mechanical therapy in treating unstable angina 
(12,13). Some of these studies are established benchmark 
examples of the randomized clinical trial, which currently is 
widely espoused by specialists and generalists alike as the 
reference standard for clinical research methods for establish- 
ing the utility of any individual therapeutic measure (14-16). 
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Concurrently and independently, medical economists and 
educators alike have developed a concept wherein primary 
care physicians or generalists would be the backbone of a novel 
dynamic health care delivery system in the United States that 
would permit increasing access into the system and decreasing 
expenditures largely based on a "gatekeeper" ole for the 
generalist (17-20). In essence, this model assumes that the vast 
majority of initial care for all (including acutely ill) patients 
would be delivered by a generalist who would also function to 
triage patients to further interventions, including but not 
limited to admission to the hospital, subspecialty consultations 
and diagnostic and therapeutic procedures. 
However, validation of the utility of the gatekeeper concept 
requires a positive effect on clinical outcome and health care 
expenditures. To date, neither prospective nor retrospective 
reports exist evaluating the utility of the gatekeeper concept in 
the management of patients with coronary artery disease. 
Moreover, despite the high profile that prospective clinical 
trials of interventions in coronary artery disease have achieved 
to date, the compliance with suggested clinical regimens for 
the treatment of patients of unstable angina by generalists or 
specialists is unknown. Accordingly, the present study sought 
to assess the impact of generalist- versus specialist-directed 
care in patients admitted to the hospital with a diagnosis of 
unstable angina on resource utilization and outcome at a large 
community hospital in southeast Michigan. Compliance with 
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the use of certain established pharmaceutical therapies and 
common diagnostic and therapeutic workup algorithms for 
patients with unstable angina was also specifically evaluated. 
Methods 
Entry into the study cohort required a discharge DRG 
diagnosis (either primary or secondary) of unstable angina. 
Eight hundred ninety patients with unstable angina admitted 
to the William Beaumont Hospital from July 1, 1992 to 
November 30, 1992 were prospectively entered into a data base 
for the purpose of chart analysis in a consecutive fashion. Two 
groups were then established on the basis of the attending 
physician of record. Internal medicine physicians were respon- 
sible for the care of 225 patients; the other 665 patients had a 
cardiologist as their physician of record. The hospital chart was 
first reviewed to determine baseline pidemiologic descriptors, 
including age; gender; admission cholesterol level; history of 
diabetes; and history of previous myocardial infarction, coro- 
nary angioplasty or coronary artery bypass urgery. Pharmaco- 
logic agents previously established by randomized controlled 
trials to be of utility in unstable angina (including aspirin, 
intravenous heparin infusion, nitroglycerin preparations, cal- 
cium channel blockers and beta-blockers) were searched for on 
the clinical record to determine their utilization. The type of 
presenting clinical pattern of angina was also analyzed. Three 
separate categories were determined on the basis of a clinical 
classification system (21,22) available for use at the time and 
included 1) acceleration of preexisting typical stable angina, 2) 
exertional angina of new onset, or 3) new onset typical or 
atypical rest angina. It was recognized at the beginning of the 
study that the third category might include a subset of patients 
who subsequently would be determined to have nonischemic 
chest pain. 
Both clinical outcomes and financial charges generated 
during the hospital period were determined. Death or new 
myocardial infarction occurring during the index hospital 
period comprised the primary clinical end point. Total charges 
during the hospital period were determined by analysis of data 
from the hospital computerized billing system and included 
such components as charges for room and board, pharmacy, 
radiology and catheterization laboratory. Actual cost data were 
not available, but in view of the comparative nature of the 
study, it was judged that the difference in resource utilization 
between the two groups would be accurately reflected by 
charges. Finally, the duration of the hospital period in days was 
determined for each patient. 
To further assess practice patterns, the frequency of use of 
noninvasive testing, heart catheterization, a gioplasty or cor- 
onary artery bypass surgery was assessed. To determine 
whether any objective prognosticator f clinical risk beyond 
clinical history was utilized by the treating physician, frequency 
of use of either treadmill testing or catheterization was deter- 
mined. 
Statistics. The statistical significance of differences be- 
tween continuous variables of the two groups was assessed with 
Table 1. Baseline Characteristics of Patient Groups 
Treatment Treatment 
by Internist by Cardiologist p 
(n - 225) (n = 665) Value 
Age (yr) 66.3 _+ 14.1 64.3 _+ 12.6 0.046 
Female gender 56.0% 44.4% 0.0025 
Cholesterol (mg/dl) 198 _+ 88 195 _+ 77 0.6223 
Diabetes 20.4% 28.3% 0.3287 
Previous myocardial infarction 31.6% 46.2% 0.0006 
Previous coronary angioplasty 7.6% 30.1% 0.0001 
Previous bypass urgery 11.1% 25.1% 0.000 l 
Any cardiac history 53.3% 80.6% 0.0001 
Data presented are mean value -+ SD or percent of patients. 
the Student unpaired t test using a two-tailed p -< 0.05 level. 
Categoric variables were evaluated using the total chi-square 
parameter (23), and p -< 0.05 was regarded as significant. 
Results  
Baseline characteristics. Table 1 summarizes the baseline 
characteristics of the two groups. It can be seen that patients 
managed by cardiologists were slightly ounger, more likely to 
be male and had a substantially higher prevalence of estab- 
lished coronary disease (80.6% vs. 53.3%, p ~ 0.0001), as 
reflected by the rates of previous myocardial infarction, coro- 
nary angioplasty or bypass urgery. There was no difference 
between the two groups with respect o baseline cholesterol 
levels or incidence of diabetes. 
Table 2 describes the differences in clinical presentation f 
the two groups. In view of the higher proportion of patients 
with a previous cardiac history in the cardiologist group, it is 
not surprising that a substantially higher proportion of these 
patients (55.4% vs. 24.9%, p -< 0,0001) presented with accel- 
eration of previous angina. Patients in the internist group were 
more likely to present with exertional angina of new onset 
(23.6% vs. 19.6%, p -< 0.001) or rest pain, typical or atypical 
(51.6% vs. 25.0%, p -< 0.001). 
Practice patterns. Pronounced differences were evident in 
the clinical practice pattern during the study period (Fig. 1). 
Cardiologists were more likely to use aspirin as an initial 
therapy for patients with unstable angina (78.2% vs. 68.4%, 
p -< 0.032) as well as heparin (84.2% vs. 67.1%, p -< 0.001). 
Beta-blockers were used in a minority of patients in either 
cohort but significantly more often by cardiologists (29.8% vs. 
Table 2. Clinical Presentation Patterns as a Function of Cohort 
Treatment by Treatment by p 
Angina Internist Cardiologist Value 
Accelerated. typical 24.9% 55.4% 0.0001 
New onset, exertional 23.6% 19.6% 0.001 
Rest or atypical 51.6% 25.0% 0.001 
Data presented are percent ofpatients. 
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Figure 1. Pharmacotherapies used for treatment of 
unstable angina. 
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17.8%, p - 0.004). Similarly, calcium channel blockers were 
used more often by cardiologists than internists (42% vs. 
21.3%, p -< 0.01). The only therapy applied equally to each 
patient cohort was nitrates (90.2% vs. 93.1%, p = 0.16). 
Figure 2 depicts the pattern of use of ancillary noninvasive 
and invasive procedures for patients with unstable angina. 
Treadmill testing was performed before hospital discharge in 
37% of internist-treated patients but in only 22% of cardiologist- 
treated patients (p <- 0.001). Conversely, the cardiology group 
was much more likely to undergo heart catheterization during 
the initial hospital period for unstable angina (61.4% vs. 
26.7%, p -< 0.0001). Altogether, either stress testing or heart 
catheterization before hospital discharge, to confirm the diag- 
nosis and risk-stratify the patient, was performed in only 56% 
of internist-treated patients, a bare majority. Conversely, 77% 
of the cardiology group underwent either modality before 
hospital discharge (p _< 0.0001). Differences in use of revascu- 
larization were also present. Patients of cardiologists (39.6%) 
underwent coronary angioplasty more often during the same 
hospital period than those of internists (6.7%, p - 0.0001). 
The difference for utilization of bypass urgery was much less 
(5.7% vs. 4.4%, cardiologists vs. internists, p <_ 0.46). Any 
coronary revascularization procedure was performed in only 
10.5% of internist-treated patients compared with 44% of 
cardiologist-treated patients (p -< 0.001). 
Outcome. Clinical outcome appeared nonsignificantly en- 
hanced among cardiologist-treated patients relative to inter- 
nist-treated patients (death in 1.8% vs. 4%, p = 0.06; new 
myocardial infarction in 10.7% vs. 9.3%, p = 0.55; either death 
or myocardial infarction in 12.9% vs. 9.9%, p = 0.21). 
With respect to resource utilization, in-hospital charges 
were nonsignificantly greater for cardiologist-treated patients 
($17,313.00 + $15,352.00 vs. $15,333.00 + $13,727.00, p = 
0.08). It should be noted that these in-house charge figures 
reflect the use of cardiac catheterization or angioplasty in 
-66% of cardiologist-treated patients versus only 28% of 
internist-treated patients (p -< 0.001), with a mean difference 
in cost of <$2,000.00 in hospital charges. Nevertheless, length 
of hospital stay was similar between cardiologist- and internist- 
treated patients (5.3 +_ 5.1 days vs. 5.56 _+ 4.7 days, p = 0.53). 
This nonsignificant trend in favor of the cardiologist cohort 
indicates that its resource utilization may have been more 
efficient inasmuch as heart catheterization, angioplasty and 
bypass urgery were likely to be performed together with initial 
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therapeutic stabilization, in the samc or less mean length of 
stay as the internist cohort. 
Discussion 
The movement for health care reform in the United States 
has achieved very high visibility and has been described by the 
current administration as the number one item on its agenda 
for legislative passage (2{I). Hospital admissions for unstable 
angina increased to 525,000 in 1990, according to the National 
Center for Health Care Statistics (1) and resulted in 2.9 million 
hospital days. Inasmuch as acute cardiovascular disease is the 
leading cause of death in the United States, and unstable 
angina is the leading cause of hospital admission for cardio- 
vascular disease, this entity is receiving intensive attention as a 
major target of health care reform. 
The proposed essential elements of health care reform are 
several: 1) It is believed that assigning direction of inpatient 
care to generalists may preserve or enhance clinical outcome 
while reducing aggregate health care expenditure (17,18). 2) It 
is believed that the quality of care may be enhanced by uniform 
conformity to practice standards, which the generalist is as- 
sumed to be more likely to follow (24). 3) A reduction in costly 
procedures may further educe the aggregate overall cost of 
care. It is believed that under such a gatekeeper model, use of 
these procedures would decrease. The intensity of support for 
this paradigm of health care administration is such that 
massive reduction of support for specialist training and aug- 
mentation of generalist training programs have already been 
proposed by governmental and educational uthorities (25). 
William Beaumont Hospital is a large community hospital 
in Southeast Michigan whose catchment area encompasses 
>2.2 million patients. It has a large general medical staff, the 
overwhelming majority of whom are internists, with a small 
proportion family practitioners. Although care on the teaching 
service (which encompassed less than a third of all patients 
with unstable angina) is based on an approved house officer 
training program in internal medicine, all care is directly 
supervised by the attending physician of record, who is defined 
at the time of the patient's admission through the emergency 
department. The attending physician either personally formu- 
lates or superviscs all medical orders. Unstable angina is the 
most common DRG diagnosis at William Beaumont Hospital, 
and as a result, we have established a data base to facilitate 
outcomes analysis for patients with this entity receiving stan- 
dard or investigational therapeutic approaches (22,26,27). 
The data assembled by the present study do not give 
positive support for the role of internists as gatekeepers in the 
treatment of patients with unstable angina. Despite a lower 
prevalence of confirmed corona U artery disease, patients 
whose care was directed by internists experienced a trend 
toward increased hospital mortality. Moreover, compared with 
cardiologists, internists were less likely to use proven effective 
medical therapies, such as aspirin and heparin, strategies to 
assess clinical risks before hospital discharge or corrective 
mechanical measures, uch as angioplasty or bypass urgery, in 
patients admitted with unstable angina. Despite this finding, 
the length of stay and hospital charges were similar between 
groups whose care was directed by either cardiologists or 
internists. 
Outcomes research has been championed as the only 
definitive measure to assess efficacy of a specified iagnostic or 
therapeutic approach (28). Established risk factors for short- 
and long-term outcome after myocardial infarction or unstable 
angina have included age, diabetes, presence of previous 
infarction or previous cardiovascular therapies (29). Patients 
treated by cardiologists had an incidence of diabetes that was 
over 33% greater, previous myocardial infarction over 50% 
greater and previous coronary angioplasty or bypass urgery at 
least 250% greater than those treated by internists. All in all, 
80.6% of cardiologist-treated patients but only 53.3% of 
internist-treated patients had a previous cardiac history. Even 
so, the incidence of death during the hospital period was more 
than two times greater (4% vs. 1.8%) for internist-treated 
patients. The relative infrequency of this event, consistent with 
previous recent data-base studies for unstable angina, pre- 
cluded this difference from achieving greater statistical 
strength (5-9). In line with previous tudies, myocardial infarc- 
tion occurred in 10.7% of internist-treated patients and 9.3% 
of cardiologist-treated patients, a nonsignificant difference. 
When the end point of either death or nonfatal myocardial 
infarction during the hospital period was analyzed, 12.9% of 
internist-treated patients and 9.9% of cardiologist-treated pa- 
tients achieved this combined end point, again a nonsignificant 
difference. 
There appeared to be a suboptimal clinical care pattern in 
patients in the internist cohort with respect o utilization of 
proven diagnostic and therapeutic modalities. Aspirin admin- 
istered on hospital admission has been found highly effective in 
ameliorating acute coronary artery disease outcome (5-8). 
Meta-analysis of these studies (30) has shown that aspirin 
reduces the risk of myocardial infarction by 48% and death by 
51% in patients admitted with acute unstable angina. Similar 
results have been achieved in patients with acute myocardial 
infarction and with stroke (29,31). Despite the established 
benefit of aspirin in cardiovascular care at our hospital in the 
study period in the second half of 1992, aspirin was utilized in 
on ly 68.4% of internist-treated patientsversus 78.2% of cardiologist- 
treated patients. 
Similarly, several studies (7,9,10,32) have established com- 
pellingly that when given by intravenous infusion during the 
course of unstable angina, heparin reduces the risk of subse- 
quent myocardial infarction and refractory angina during the 
same hospital period. Despite these data, heparin infusion was 
used in only 67% of internist-treated patients versus 84% of 
cardiologist-treated patients. Although the data for routine use 
of beta-blockers for unstable angina are less compelling with 
respect o showing only a trend toward reduction in nonfatal 
infarction and death in single studies (2,9), meta-analysis 
showed a 13% reduction in risk of progression to acute 
myocardial infarction (31). In acute myocardial infarction, 
unequivocal benefit of beta-blockade with respect o symptom 
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control and survival (33-36) had been demonstrated. Neverthe- 
less, beta-blockers were utilized in only 29.8% of cardiologist- 
treated patients, and even more surprising, they were used in 
only 17.8% of internist-treated patients. Across the board, a 
substantially lower proportion of internist-treated patients 
received proven therapeutic agents for treatment inthe United 
States. These differences have influenced the survival differ- 
ence between the two groups. 
Although clinical stabilization of unstable angina by the 
time of hospital discharge is associated with a lower risk of 
mortality from myocardial infarction over the subsequent 3 to 
6 months, a substantial number of patients remain at high risk 
for subsequent death or myocardial infarction. These patients 
may be identified by predischarge stress testing or coronary 
arteriography orboth. The use of noninvasive tests of exercise 
duration -<6 min; exercise-induced ST segment deviation; 
exercise limited by angina; exertional hypotension; or scinti- 
graphic redistribution i two or more zones, with or without 
increased lung uptake, will identify patients with a first-year 
cardiac mortality rate >-4% and subsequent risk of myocardial 
infarction of 20% to 30% (37,38). By coronary arteriography, 
the findings of impaired ventricular function in the presence of 
multivessel disease or critical coronary artery stenosis ->90% 
severity, or both, have been associated with ominous short- 
term prognosis (39,40). Unless recent noninvasive or invasive 
testing has preceded the hospital period, most authorities 
recommend the performance of routine noninvasive testing 
before hospital discharge, when a so-called conservative strat- 
egy is used, or routine heart catheterization for patients with 
unstable angina, when a so-called routine invasive strategy is 
used (41). Nevertheless, in our study only 37% of internist- 
treated patients performed treadmill stress testing or other 
forms of physiologic stress testing, and 26.7% underwent heart 
catheterization, resulting in only 56.3% of the internist cohort 
with an objective test to confirm the diagnosis for risk stratifi- 
cation. Conversely, an aggregate 77% of patients had such 
testing by hospital discharge in the cardiologist cohort. It is 
recognized that in both cardiologist- and internist-treated 
groups, some patients may have had either form of testing after 
hospital discharge in an effort to keep the inpatient stay at a 
minimum; however, this is unlikely in view of the >5-day 
length of the hospital period. Although failure to obtain exact 
risk prognostication at the time of discharge obviously does not 
affect in-hospital outcome, it may well result in higher subse- 
quent morbidity and mortality. 
Limitations of the study. By its necessarily observational 
nature, this study was retrospective. However, with respect o 
outcomes analysis, a retrospective design in which individual 
clinicians are not aware of monitoring of outcome appears to 
be inherently advantageous over a prospective design with 
respect o ascertainment of actual clinical utilization patterns. 
The two groups were clearly not matched in terms of baseline 
characteristics. Nevertheless, we believe that the two groups 
are representative of what may be found at other community 
hospitals in the United States. The internist-treated group not 
unexpectedly had a lower prevalence of previous established 
cardiovascular disease. However, patients treated by internists 
presented more frequently with pain at rest. The failure to 
distinguish between typical rest angina of new onset, which 
would carry with it higher than usual mortality and morbidity 
risk, and atypical chest pain at rest, which would suggest a 
noncardiac diagnosis, is a significant limitation of the study. If 
the internist-treated patients truly had rest angina of new 
onset, this may explain the higher probability for adverse 
short-term outcome observed in this group. However, this is 
unlikely in view of the surprisingly lower frequency with which 
proven therapeutic modalities and diagnostic testing were used 
in this subgroup. The data suggest hat either a potentially 
higher risk of the subset was not detected by the treating 
clinician or, more likely, that atypical noncardiac symptoms 
were suspected. 
Implication for clinical policy making. Our study suggests 
that at our hospital, at least, direction by internists of care for 
patients with unstable angina did not enhance quality of care 
or clinical outcome or reduce health care expenditures. Several 
corrective measures may be used to enhance the outcome and 
clinical care paradigm of the generalist group. 
Definitive clinical practice guidelines for the management 
and diagnosis of unstable angina should be used and were 
recently drafted by a panel of experts compiled by the Agency 
of Health Care Policy and Research under the directive of 
Congress (41). If these guidelines are accepted by appropriate 
representatives of the generalist and specialist communities 
involved in the delivery of cardiovascular care for unstable 
angina, it should then be expected that relatively rigid adher- 
ence to these protocols might well enhance quality of care if 
not also the outcome. At each institution considering use of 
such a gatekeeper role for their generalists, it is suggested that 
an outcomes analysis similar to that done at our hospital be 
employed. Moreover, once a gatekeeper strategy is in use, 
consideration may be given to annual or biannual reassessment 
of its clinical efficacy and effect on outcome. Finally, physi- 
cians, health care planners and administrators need to recog- 
nize the possibility that the driving force for health care reform 
(i.e., that the high standard of care provided by specialists may 
be provided at a relatively lower level of expenditure by 
generalists) is at best a well intended but axiomatic oncept not 
yet supported by the available clinical data. 
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